Neurocrine Biosciences Inc Stock Price, News & Analysis

Neurocrine Biosciences (Nasdaq: NBIX) reported Phase 2 SAVITRI results showing that once-daily 1 mg osavampator produced statistically significant and clinically meaningful reductions in depression severity at Day 28 and Day 56 versus placebo in adults with major depressive disorder with inadequate response to antidepressants. The randomized 2:1:1 study enrolled 183 adults. Osavampator was generally well tolerated with no serious adverse events; common TEAEs included headache and nasopharyngitis. An exploratory exposure-response analysis supports continuing 1 mg into planned Phase 3 studies.

Neurocrine Biosciences (Nasdaq: NBIX) said members of its management team will present at two investor conferences: a Jefferies Global Healthcare Conference fireside chat on November 18, 2025 at 12:00 PM GMT (7:00 AM ET) in London, and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 2, 2025 at 9:30 AM ET in New York.

Both presentations will be live webcast via the company's Investors page at www.neurocrine.com. Replays will be posted about one hour after each event and will be archived for approximately one month.

Neurocrine Biosciences (Nasdaq: NBIX) announced top-line results from a Phase 2 signal-seeking study of NBI-1070770 in adults with major depressive disorder (MDD) on Nov 10, 2025.

The study enrolled 73 adults with inadequate response to at least one antidepressant. The compound did not meet the primary endpoint versus placebo. NBI-1070770 was reported to be generally well tolerated. Company management said it will continue data analyses to determine next steps.

Neurocrine Biosciences (Nasdaq: NBIX) reported third-quarter 2025 results on Oct 28, 2025: Total net product sales $790M (+28% YoY, +16% sequential).

INGREZZA sales were $687M (+12% YoY, +10% sequential) with record new patient starts; CRENESSITY sales were $98M with 540 new patient enrollment start forms and ~80% reimbursement coverage.

Third-quarter GAAP net income was $209.5M (EPS $2.04); non-GAAP net income was $222.1M (EPS $2.17). Cash and marketable securities totaled about $2.11B. Company reaffirmed full-year INGREZZA guidance of $2.5B–$2.55B and provided 2025 R&D and SG&A ranges.

Neurocrine Biosciences (NASDAQ: NBIX) presented a post‑hoc analysis from the Phase 3 KINECT 4 study showing that continuous treatment with INGREZZA 40 mg once daily produced rapid, sustained, clinically meaningful improvements in tardive dyskinesia (TD) over 48 weeks.

Key outcomes: mean AIMS total score change exceeded the minimally clinically important difference at all post‑baseline visits; 90% (18/20) of participants who completed 48 weeks on continuous 40 mg reached ≥50% AIMS improvement; patients who reduced from 80 mg to 40 mg showed similar benefit. Safety was consistent with the known profile, with most adverse events mild/moderate and the most common being sleepiness and tiredness. Findings were presented October 15–18, 2025 at the American Psychiatric Nurses Association conference.

Neurocrine Biosciences (NASDAQ: NBIX) will release its third quarter 2025 financial results and host a conference call and webcast on October 28, 2025. The press release is scheduled for 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET.

Dial-in numbers: Domestic 800-274-8461, International 203-518-9814 with Conference ID: NBIX. The webcast will be available on the company's Investors page at neurocrine.com, with a replay posted about one hour after the event and archived for ~one month.

Neurocrine Biosciences (Nasdaq: NBIX) announced on October 6, 2025 the appointment of Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise.

Sibley will lead sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA franchise. He brings more than 20 years of commercial biopharma experience and joins after a nine-year tenure at Sanofi, most recently as General Manager for US Dermatology. Prior roles include positions at Galderma, J.P. Morgan Chase & Co., and Johnson & Johnson. Sibley holds a Bachelor of Arts in Economics from the University of Massachusetts, Amherst.

Neurocrine Biosciences (Nasdaq: NBIX) presented three-year open-label KINECT-HD2 data showing once-daily INGREZZA (valbenazine) produced early and sustained reductions in Huntington's disease chorea with an established long-term safety profile.

Key results: 154 adults treated up to 156 weeks; mean UHDRS Total Maximal Chorea improvement by Week 2 was -3.4±0.3 (n=146); PGI-C responders rose from 34.5% at Week 2 to 77.8% at Week 156. TEAEs were consistent with known safety: 97.4% reported ≥1 TEAE; most common were falls (42.9%), somnolence (25.3%), fatigue (21.4%); discontinuations due to TEAEs were 15.6%.

Neurocrine Biosciences (NASDAQ:NBIX) announced new post-hoc analysis data from their Phase 4 KINECT-PRO™ study of INGREZZA® (valbenazine) for tardive dyskinesia (TD) treatment. The study showed that 57.8% of patients (26 of 45) achieved symptomatic remission at Week 24, with success rates of 58.3% at 40mg, 44.4% at 60mg, and 62.5% at 80mg doses.

The analysis demonstrated significant improvements in patient-reported outcomes among those achieving remission, including enhanced quality of life and reduced disease burden. Notably, patients showed substantial improvements across multiple measures: the Tardive Dyskinesia Impact Scale (TDIS™), Sheehan Disability Scale (SDS), and EuroQoL Visual Analog Scale (EQ-VAS). The safety profile remained consistent with previous findings, with no new concerns identified.